The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.
May 14th 2024
Closer monitoring of youth hypertension could lessen the disease in adults, reducing overall costs and morbidity related to cardiovascular disease (CVD), new research shows.
Nationwide Data Show Delayed Correct Diagnosis for PAH
February 6th 2023The long time to diagnosis is consistent with data pointing to pulmonary arterial hypertension (PAH) often being misdiagnosed as asthma, said the researchers, adding that the findings from their retrospective study provide valuable insight into where the diagnostic pathway lags.
Read More
Fetal Outcomes, Maternal Mortality Vary Among Pregnant Women With Different Types of PH
January 19th 2023A small study conducted in China suggests pregnant women with idiopathic pulmonary arterial hypertension (iPAH) are at higher risk of maternal mortality compared with women with certain other types of pulmonary hypertension (PH).
Read More
Contraction, Mortality Rate of COVID-19 Was Lower in Vaccinated Patients With PAH
January 9th 2023Patients with pulmonary arterial hypertension (PAH) were more likely to die or be hospitalized if they contracted COVID-19 but were less likely to die from COVID-19 if they were vaccinated against SARS-CoV-2.
Read More
Hypertension Knowledge, Training Lacking Within Internal Medicine Programs
November 17th 2022Despite the commonality of hypertension among US adults—nearly half of them have elevated blood pressure—hypertension education among internal residents has not kept up with the condition’s prevalence.
Read More
Macitentan Safety, Effectiveness in PAH Confirmed in New Analysis
November 3rd 2022Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.
Read More
Potential Risk Factors Identified for RRT Among Patients With PH
October 24th 2022According to the study authors, acute decompensated pulmonary hypertension (PH) is often accompanied by systemic congestion and right ventricular flow output, and because PH can be accompanied by acute kidney injury, renal replacement therapy (RRT) may be necessary.
Read More
Syncope May Increase Vasoreactivity Among Pediatric Patients With PAH
October 19th 2022Although group 1 pulmonary arterial hypertension (PAH) with comorbid syncope has been linked to a poor prognosis among adults, this relationship remains uncertain in pediatric patients, prompting a new study.
Read More
Sepsis, Septic Shock Likely Increase Risk of Adverse Outcomes in PAH
October 11th 2022Investigators for this study analyzed outcomes among patients hospitalized with pulmonary arterial hypertension (PAH) who have higher risks of adverse health outcomes, in particular sepsis and septic shock.
Read More
Potential for PHC Necessitates Pediatric Cardiology Care for Children With PAH
September 28th 2022Outcomes following right heart catheterization in a pediatric patient population were analyzed, with emphasis placed on risk of adverse outcomes following the procedure, especially the development of pulmonary hypertensive crisis (PHC).
Read More
Potential for Precision Medicine Approach in PAH Explored in New Study
September 16th 2022This new study of pulmonary arterial hypertension (PAH) among women examined the in-common symptoms of different disease phenotypes to see where they overlap and ultimately to define the “symptome” according to symptom cluster and characteristics.
Read More
Mortality Worsens Following Borderline PH Diagnosis Among Patients With LHF
September 8th 2022Following a recent update to the diagnostic criteria for borderline pulmonary hypertension (PH), which is often associated with left heart failure (LHF), outcomes among patients with both conditions remain uncertain.
Read More
Results of Macitentan in PAH From SERAPHIN OL Echo Earlier Trial Safety Data
September 1st 2022This open-label extension of the SERAPHIN trial evaluated the long-term safety and tolerability of a small daily dose of the endothelin receptor antagonist against pulmonary arterial hypertension (PAH) among patients from the original study.
Read More
Risk of PH Increases With Preterm Birth
August 16th 2022Infants born between the 23rd and 25th weeks of pregnancy, classified as extremely low gestational age newborns, are surviving in increasing numbers, note study authors, and with that is growing clinical interest in their long-term sequelae, including pulmonary hypertension (PH).
Read More
How Much Do Physicians Know About SDOH in Their Patients With PAH?
July 28th 2022Clinicians interviewed in a recent study reported various social determinants of health (SDOH) affecting health outcomes for patients with pulmonary arterial hypertension (PAH), indicating the need to address SDOH in PAH care.
Read More
Functional Capacity Dropped Among Patients With PAH Following COVID-19 Lockdown
July 12th 2022A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).
Read More
New Findings May Have Implications for PH Classification
July 8th 2022Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.
Read More
Study Highlights Need for Validated Blood Biomarkers in PAH
June 23rd 2022Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.
Read More